AXSM Axsome Therapeutics Inc
Company Analysis
Latest News
Axsome Prepares Auvelity Alzheimer's Launch, Presents New SYMBRAVO Migraine Data
Axsome Therapeutics is preparing the imminent launch of Auvelity for the treatment of agitation in Alzheimer’s patients. This expansion introduces the product...
🟢 Axsome Therapeutics Inc is trading 4.2% up today amid bullish analyst sentiment and its annual shareholder meeting
Axsome Therapeutics Inc is trading 4.2% up today at $241.19 as investors react positively to the company's 2026 annual shareholder meeting and sustained...
Axsome Settles All SUNOSI Patent Litigation, Delaying Generic Entry Until 2040
Axsome Therapeutics announced it has resolved all patent litigation for its product SUNOSI® (solriamfetol). The settlement agreements with five generic drug...
Axsome Locks Down Its Sleep Drug From Generics Until 2040 — But Can It Grow Fast Enough to Justify the Bet?
Shares of Axsome Therapeutics surged 6.9% to $237.40 after the company announced it has now settled all outstanding patent litigation over its wakefulness...
🟢 Axsome Therapeutics Inc is trading 7.1% up today after settling all SUNOSI patent litigation
Axsome Therapeutics Inc is trading 7.1% up at approximately $237–238 in pre-market trading after announcing a comprehensive settlement of all SUNOSI...
🟢 Axsome Therapeutics Inc is trading 7.1% up today after settling SUNOSI® patent litigation
Axsome Therapeutics Inc is trading 7.1% up at $238.00 in pre-market action after the company announced a significant legal development. * The company...
🔴 Axsome Therapeutics Inc is trading 4.5% down today in a likely profit-taking pullback
Axsome Therapeutics Inc is trading 4.5% down today at $219.83 as investors appear to lock in profits following a strong run driven by earlier positive...
🔴 Axsome Therapeutics Inc is trading 4.2% down today in a likely profit-taking move
Axsome Therapeutics Inc is trading 4.2% down at $220.64 as the stock gives back a portion of its recent gains following a period of positive regulatory and...